Regeneron To Stop Giving Placebo In COVID-19 Antibody Trial After 'Clear Efficacy'

by Vandana Singh, Benzinga Editor

February 25, 2021 8:57 AM | 1 min read |

Following recommendations from the Independent Data Monitoring Committee (IDMC), Regeneron Pharmaceuticals Inc (NASDAQ: REGN) will make changes to the Phase 3 trial evaluating REGEN-COV (casirivimab with imdevimab) in outpatients with COVID-19.
The company said that an independent panel found the company's COVID-19 antibody cocktail at both 1,200mg and 2,400mg doses have "clear clinical efficacy" in reducing the rates of hospitalization and deaths in patients.
The panel has recommended that Regeneron should stop enrolling patients in the placebo group.
The cocktail was authorized in November for emergency use by the FDA.
The company plans to share details of unblinded data from the trial once it becomes available in March.
Price Action: REGN is marginally up by 0.5% at $460.9 in premarket trading on the last check Thursday.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.